Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023
In: Business Wire, 2023-04-17, S. 3
Zeitungsartikel
Zugriff:
Boundless Bio, a clinical stage next generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14 19, 2023. The poster "Tumors driven by oncogene amplified extrachromosomal DNA (ecDNA) demonstrate enhanced sensitivity to cell cycle checkpoint kinase 1 (CHK1) inhibition" is available for in person presentation on April 17, 2023 at 9:00 a.m...
Titel: |
Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023
|
---|---|
Autor/in / Beteiligte Person: | James Lee Director of Business Development Boundle |
Zeitschrift: | Business Wire, 2023-04-17, S. 3 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|